Our findings identify ST6GAL1 and sialoglycans as major contributors to prostate cancer bone metastasis and highlight a new opportunity to combine sialic acid blockade with existing anti-androgen and immunotherapy treatments to develop urgently needed new combination therapies for advanced prostate cancer. This evidence concerns the gene ST6GAL1 and Familial prostate cancer.